The global cancer biomarker testing market was valued at USD 10.42 billion in 2021 and is anticipated to grow at USD 20.59 billion by 2028 recording a CAGR of 12.4% during the forecast period 2022-2028.The capacity to identify appropriate patients for treatment based on molecular biomarkers propelled the targeted therapy oncology market to new heights. Breast cancer, gastric cancer, colorectal...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian